Results 101 to 110 of about 24,740 (199)

Might modulation of the endocannabinoid system provide a potential dual therapeutic strategy for osteoporosis and depression?

General Psychiatry, Volume 39, Issue 4, August 2026.
Peng Wei, Pianpian Zhao, Zenghui Gu, Mengyuan Yang, David Karasik, Ching‐Lung Cheung, Houfeng Zheng   +6 more
wiley   +1 more source

5‐HT2A receptor agonism by tert‐leucinamide and valinamide synthetic cannabinoids: In vitro and in vivo evidence

British Journal of Pharmacology, Volume 183, Issue 16, Page 4715-4734, August 2026.
Abstract Background and Purpose New synthetic cannabinoid receptor agonists (SCRAs) are associated with severe adverse effects, including unexpected psychiatric symptoms. These compounds are mainly active through their potent agonism on the cannabinoid receptors CB1 and CB2.
Giorgia Corli, Deborah Rudin, Dino Luethi, Matthias E. Liechti, Sabrine Bilel, Matteo Marti, Henrik Green, Manuela Carla Monti, Caitlyn Norman   +8 more
wiley   +1 more source

Inhibition of peripheral CB1 receptors modulates food intake and metabolic efficiency in obesity independently of the gut–brain vagal axis

British Journal of Pharmacology, Volume 183, Issue 16, Page 4953-4968, August 2026.
Background and Purpose Obesity involves profound disruptions in neuronal circuits, neuroendocrine communication and the endocannabinoid system. While global blockade of cannabinoid CB1 receptors improves metabolism, its clinical use is limited by neuropsychiatric side effects.
Oriane Onimus, Camille de Almeida, Benoit Bertrand, Julien Castel, Nejmeh Mashhour, Anthony Ansoult, Serge Luquet, Giuseppe Gangarossa   +7 more
wiley   +1 more source

The Endocannabinoid System in Neuropsychiatric Disorders: Mechanisms, Dysregulation and Therapeutic Potential. [PDF]

Biomedicines
Mušić T, Turnšek TL.
europepmc   +1 more source

Neuropeptides and endocannabinoid system as regulators of blood pressure in adolescents with primary hypertension. [PDF]

Medicine (Baltimore)
Martyniak A, Wójcicka M, Drożdż D, Tomasik PJ.   +3 more
europepmc   +1 more source

Endocannabinoid System-Related Inflammation and Progression of Autosomal Dominant Polycystic Kidney Disease. [PDF]

Int J Mol Sci
Simankowicz P, Dołęgowska B, Marchelek-Myśliwiec M, Dołęgowska K, Różański J, Stępniewska J.   +5 more
europepmc   +1 more source

The role of the endocannabinoid system in managing neuropsychiatric symptoms in Alzheimer's disease. [PDF]

Front Psychiatry
Rao JS, Alejandra Tangarife M, Venegas MM, Forero B, González Tamayo LL, Escobar-Gallego JP, Rodríguez-Soacha DA, Ferreiros A, Mukunda R.   +8 more
europepmc   +1 more source

Modulation of the endocannabinoid system reduces inflammatory signalling in canine mammary carcinoma cells. [PDF]

Vet Rec Open
Franco GA, Marino Y, Rifici C, Fusco R, di Paola D, Cuzzocrea S, Catone G, Vullo C, Gugliandolo E.   +8 more
europepmc   +1 more source

Editorial: The role of cannabinoids and the endocannabinoid system in anti-cancer therapy. [PDF]

Front Pharmacol
Franks LN, Raup-Konsavage W, Fonseca BM.
europepmc   +1 more source

Correction: Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis. [PDF]

Front Neurol
Annovazzi P, Clerico M, Cocco E, Conte A, Marfia GA, Salvetti M, Tomassini V, Totaro R, Centonze D.   +8 more
europepmc   +1 more source